Compare PROV & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | PMN |
|---|---|---|
| Founded | 1956 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 115.5M |
| IPO Year | 2009 | 2022 |
| Metric | PROV | PMN |
|---|---|---|
| Price | $17.13 | $10.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $16.25 | ★ $42.67 |
| AVG Volume (30 Days) | 6.2K | ★ 18.1K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $25.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.95 | $0.29 |
| 52 Week High | $17.42 | $27.40 |
| Indicator | PROV | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 47.99 |
| Support Level | $16.91 | $9.20 |
| Resistance Level | $17.39 | $11.37 |
| Average True Range (ATR) | 0.29 | 0.73 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 74.46 | 55.38 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.